Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 2INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Neoplasms 30Prostatic Neoplasms 22Neoplasm Metastasis 20Breast Neoplasms 17Lung Neoplasms 16Colorectal Neoplasms 15Leukemia, Myeloid, Acute 14Pancreatic Neoplasms 13Ovarian Neoplasms 12Urinary Bladder Neoplasms 11Lymphoma 11Hematologic Neoplasms 11Carcinoma, Non-Small-Cell Lung 10Stomach Neoplasms 9Myelodysplastic Syndromes 9Squamous Cell Carcinoma of Head and Neck 8Sarcoma, Kaposi 8Pheochromocytoma 8Multiple Myeloma 8Melanoma 8Lymphoma, Non-Hodgkin 8Leukemia, Lymphocytic, Chronic, B-Cell 8Endometrial Neoplasms 8Carcinoma, Renal Cell 8Burkitt Lymphoma 8Neuroendocrine Tumors 7Mouth Neoplasms 7Kidney Neoplasms 7Glioma 7Thyroid Neoplasms 6

Interventions

decitabine and cedazuridine drug combination 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × NIH × GATA2 Deficiency × Clear all
NCT01905826 2026-06-05

Natural History Study of GATA2 Deficiency and Related Disorders

National Institutes of Health Clinical Center (CC)

Recruiting
600 enrolled
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Herpes Simplex, Leukemia, Myelodysplastic Syndromes

NCT06484062 2026-05-13

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 1 Recruiting
54 enrolled
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡